In particular:•the growth of our business is substantially dependent on increased market penetration for the appropriate use of DEFINITY in suboptimal echocardiograms;•we face continued pricing pressures from our competitors, large customers and group purchasing organizations;•in the United States, we are heavily dependent on a few large customers and group purchasing organization arrangements to generate a majority of our revenues for our medical imaging products and outside of the United
reductions in third party coverage and reimbursement rates for our products could adversely affect our business and results of operations;•our history of net losses and ability to achieve sustained profitability; and•we have a substantial amount of indebtedness that may limit our financial and operating activities and adversely affect our ability to incur additional debt to fund future needs, and we may not be able to generate
Financial Condition and Results of Operations” and our consolidated financial statements and the related notes thereto included elsewhere in this prospectus.Three Months ended March 31,Year ended December 31,20152014201420132012(dollars in thousands except share and per share data)Revenues$74,823$73,336$301,600$283,672$288,105Cost of goods sold39,05443,275176,081206,311211,049Loss on firm purchase commitment————1,859Total cost of goods sold39,05443,275176,081206,311212,908Gross profit35,76930,061125,51977,36175,197Operating expensesSales and marketing expenses9,0729,49835,11635,22737,437General and administrative expenses9,1238,85237,31333,03632,520Research and development expenses6,1963,22213,67330,45940,604Proceeds from manufacturer———(8,876)(34,614)Impairment on land———6,406—Total operating expenses24,39121,57286,10296,25275,947Operating income (loss)11,3788,48939,417(18,891)(750)Interest expense(10,630)(10,560)(42,288)(42,915)(42,014)Interest income7827104252Other income (expense), net(383)(414)4781,161(44)Income (loss) before income taxes372(2,477)(2,366)(60,541)(42,556)Provision (benefit) for income taxes(3)(1,192)1,1951,014(555)Net income (loss)$375$(1,285)$(3,561)$(61,555)$(42,001)14Table of ContentsThree Months ended March 31,Year ended December 31,20152014201420132012(dollars in thousands except share and per share data)Net income (loss) per common share:Basic and diluted, historical$0.01$(0.03)$(0.07)$(1.21)$(0.84)Basic and diluted, pro forma(1) (unaudited)$0.02$(0.07)$(0.20)$(3.41)$(2.35)Common shares:Basic, historical50,807,50350,803,48450,806,51250,670,27450,250,957Diluted, historical51,716,32750,803,48450,806,51250,670,27450,250,957Basic, pro forma(1) (unaudited)18,080,94418,079,53718,080,61518,032,13117,882,908Diluted, pro forma(1) (unaudited)18,404,39318,079,53718,080,61518,032,13117,882,908Pro forma as adjusted net income (loss) per common share(2) (unaudited):Basic$0.18$0.12$0.53Diluted$0.18$0.12$0.52Pro forma as adjusted common shares(2) (unaudited):Basic25,975,68025,974,27325,975,351Diluted26,299,12926,363,88326,337,384Three Months ended March 31,Year ended December 31,20152014201420132012(dollars in thousands)(unaudited)Other Financial Data:Adjusted EBITDA(3)$20,587$16,018$70,755$38,483$21,598As of March 31, 2015ActualPro forma(1)Pro formaas adjusted(4)(dollars in thousands)Consolidated Balance Sheet Data:Cash and cash equivalents$30,743$30,743$22,726Total assets250,658250,658241,777Total liabilities489,634489,634443,636Revolving credit facility8,0008,000—Current portion of long-term debt———Total long-term debt, net399,348399,348361,350Total stockholders’ deficit(238,976)(238,976)(201,859)(1)Pro forma information gives effect to our corporate reorganization, which will have no impact on our historical net income (loss) or balance sheet data, however, it will reduce the number of common shares and net income
following table provides a reconciliation of our net income (loss) to Adjusted EBITDA for the periods presented:Three Months ended March 31,Year ended December 31,2015201420142013(i)2012(i)(dollars in thousands)(unaudited)Net income (loss)$375$(1,285)$(3,561)$(61,555)$(42,001)Interest expense, net10,62310,55242,26142,81141,762Provision for income taxes(a)1(1,017)441(127)(901)Depreciation and amortization7,5844,51619,02425,78327,955EBITDA18,58312,76658,1656,91226,815Non-cash stock-based compensation2772841,0315781,240Legal fees(b)172341,1136601,455Loss on firm purchase commitment(c)————1,859Asset write-off(d)1804201,25728,34913,095Severance and recruiting costs(e)97858185,2391,761Sponsor fee and other(f)5712513,4121,4571,042New manufacturer costs(g)8621,9784,9594,1648,945Proceeds from manufacturer———(8,876)(34,614)Adjusted EBITDA(h)$20,587$16,018$70,755$38,483$21,598(a)Represents provision for income taxes, less tax indemnification associated with an agreement with BMS.(b)Represents legal services expenses incurred in connection with our business interruption claim associated with the NRU reactor shutdown in 2009 to 2010.(c)Represents a loss associated with a portion of the committed purchases of Ablavar that we do not believe we will be able to sell prior to expiration.(d)Represents non-cash losses incurred associated with the write-down of land, intangible assets, inventory and write-off of long-lived assets.
December 31, 2012 amount consists primarily of a $10.6 million inventory write-down related to Ablavar.16Table of Contents(e)Represents primarily severance and recruitment costs related to employees, executives and directors.(f)Represents annual sponsor monitoring fee and related expenses, non-recurring professional fees and certain non-recurring charges relating to a customer relationship.(g)Represents internal and external costs associated with establishing new manufacturing sources for our commercial products and agents in development.(h)Does not include run-rate cost savings, operating expense reductions and other expense and cost-savings of $14.4 million and $2.9 million, which were realized for the years ended December 31, 2013 and 2012,
without otherwise increasing the overall usage of ultrasound contrast agents, our current and future sales volume could suffer, which would have a material adverse effect on our business, results of operations, financial condition and cash flows.In the United States, we are heavily dependent on a few large customers and group purchasing organization arrangements to generate a majority of our
their term, or are not renewed, or are renewed on terms that are less favorable to us, then such an event could have a material adverse effect on our business, results of operations, financial condition and cash flows.Our written supply agreements with Cardinal relating to TechneLite, Xenon, Neurolite, Cardiolite and certain other products expired in
our current unit pricing, which, in turn, could have a material adverse effect on our business, results of operations, financial condition and cash flows.Our dependence upon third parties for the manufacture and supply of a substantial portion of our products could prevent us from delivering our products to
able to do so in the future, our margins may decline further with respect to our TechneLite generators, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.The Moly supply shortage caused by the 2009-10 NRU reactor shutdown has had a negative effect on the demand for some of our products, which will likely
not able to pass along to our customers any change of terms from our supplier, there could be a negative effect on our business, results of operations, financial condition and cash flows.Currently, we are the leading provider of packaged Xenon in the United States.
forced to further reduce the price of our Cardiolite products as well as lose additional market share, which would have an adverse effect on our business, results of operations, financial condition and cash flows.In addition, because several of the products we manufacture became less available due to recent supply challenges, certain of our customers
aggregate number of diagnostic medical imaging procedures performed in the United States, our business, results of operations, financial condition and cash flows would be adversely affected.
DEFINITY could limit expanded use of DEFINITY and have a material adverse effect on the unit sales of this product and our financial condition and results of operations.Our business depends on our ability to successfully introduce new products and adapt to a changing technology and diagnostic landscape.The healthcare industry is characterized by continuous technological development resulting in changing customer preferences and requirements.
overhead allocable to the remaining market share, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.The process of developing new drugs and obtaining regulatory approval is complex, time-consuming and costly, and the outcome is not certain.We currently have three agents in development, two of which (flurpiridaz F 18 and 18F LMI 1195) are currently in clinical development,
If we are unable to establish or maintain these strategic partnerships, we will have to limit the size or scope of, or delay, our development programs.In addition, our dependence on strategic partnerships is subject to a number of risks, including:•the inability to control the amount or timing of resources that our partners may devote to developing the agents;•the possibility that we may be required to relinquish important rights, including economic, intellectual property, marketing and distribution rights;•the receipt of lower revenues than if we were to commercialize those agents ourselves;•our failure to receive future milestone payments or royalties if a partner fails to commercialize one of our agents successfully;•the possibility that a partner could separately move forward with competing agents developed either independently or in collaboration with others, including our competitors;•the possibility that our strategic partners may experience financial or operational difficulties;•business combinations or significant changes in a partner’s business strategy that may adversely affect that partner’s willingness or ability to complete its obligations under any arrangement with us; and•the possibility that our partners may operate in countries where their operations could be negatively impacted by changes in the local regulatory environment or by political unrest.Any of these factors either alone or taken together could have a material adverse effect on our future business, results of operations,